Scenario | 1 | 2 | 3 | 4 |
---|---|---|---|---|
Analyzable (N) | 8334 | 8454 | 8570 | 5801 |
Gleason grade biopsy | ||||
3 + 4 vs. ≤3 + 3 | 1.94*** | |||
4 + 3 vs. 3 + 4 | 1.63*** | |||
≥4 + 4 vs. 4 + 3 | 1.39*** | |||
cT stage | ||||
T2a vs. T1c | 1.53*** | 1.47*** | ||
T3a vs. T2c | 0.65* | 1.07 | ||
Preoperative PSA level | ||||
4–10 vs. < 4 | 1.25* | 1.21* | 1.11 | 1.14 |
10–20 vs. 4–10 | 1.58*** | 1.41*** | 1.25*** | 1.16* |
> 20 vs. 10–20 | 1.67*** | 1.47*** | 1.23* | 1.22* |
PSCA expression | ||||
Positive vs. negative | 0.84*** | 0.86** | 0.93 | 0.93 |
Gleason grade prostatectomy | ||||
3 + 4 vs. ≤3 + 3 | 2.91*** | 2.39*** | 2.30*** | |
4 + 3 vs. 3 + 4 | 2.72*** | 2.24*** | 2.05*** | |
≥4 + 4 vs. 4 + 3 | 1.75*** | 1.25* | 1.21* | |
pT stage | ||||
T3a vs. T2 | 1.94*** | 1.94*** | ||
T3b vs. T3a | 1.73*** | 1.52*** | ||
T4 vs. T3b | 1.20 | 1.24 | ||
Surgical margin (R) status | ||||
R1 vs. R0 | 1.40*** | 1.18* | ||
Nodal (pN) stage | ||||
N+ vs. N0 | 1.56*** |